🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Anti-myostatin muscle-growing antibody #apitegromab has been submitted to the FDA for approval. nature.com/articles/d4157…

Systematic review of clinical guidelines on inpatient hyperglycemia management that vary on treatment targets and home medication use and lack guidance on discharge transition. @TimAndersonMD ADA Professional Publications Read Here➡️ diabetesjournals.org/care/lookup/do…

Diagnostic Approach to Abnormal Alkaline Phosphatase Value - Mayo Clinic Proceedings🔴✅ mayoclinicproceedings.org/article/S0025-…

Although weight loss in people with #obesity has many health benefits, it can also have adverse #skeletal effects, with increased #bone loss and #fracture risk thelancet.com/journals/landi… #BMD #osteoporosis #weightloss #BariatricSurgery #GLP-1 receptor agonists

🔴Common Mistakes in BP Measurement⤵️ #medtwitterWhat #MedTwitter #CardioEd #medx #medEd #CardioTwitter #cardiotwitter #MedX #MedEd #cardiology #cardiotwiteros #FOAMed #medicine #cardiox #medical #cardiovascular #medtwitter #medtwitter #paramedic

Great debate: Plasma triglycerides are an important causal factor and therapeutic target for atherosclerotic cardiovascular disease: Jan Boren+Chris Packard vs. Børge Nordestgaard. academic.oup.com/eurheartj/adva… Who wins? Here are the arguments - you decide - open acces

Out today! 30th anniversary special on #Graves #EndocrinePractice by Sina Jasim Management Aspects of Medical Therapy in Graves Disease - Endocrine Practice endocrinepractice.org/article/S1530-…

High lipoprotein(a) levels, defined as 50 mg/dL or greater, are associated with increased rates of atherosclerotic cardiovascular disease events and all-cause mortality. This JAMA Insights discusses lipoprotein(a). ja.ma/3GnbYlc

Is anticoagulation useful in device detected PAF / High rate episodes ? jamanetwork.com/journals/jaman…

Dr. Philip R. Schauer and Dr. Amy E. Rothberg go head-to-head in the Point-Counterpoint Debate: Surgery vs Medical Treatment for the Management of Obesity. 🔹 Surgery: Metabolic procedures yield significant, sustained weight loss and diabetes remission but come with surgical

Christie Ballantyne speaks on Lp(a) #EASCongress2025 🫀Lp(a) is proatherogenetic, pro inflammatory and pro thrombotic 🫀continuous increase and same association by race 🫀 units remain inconsistent how they are reported 🫀 Measure it once in all

#EASCongress2025 session on #HDL with well known experts

Honored and privileged to be part of this collaborative work on MRONJ and Dental Implants in patients with Osteoporosis!! AACE #EndocrinePractice #MedTwitter Article 🔗 kwnsfk27.r.eu-west-1.awstrack.me/L0/https:%2F%2…

Type 2 #diabetes and accelerated #ageing in skeletal #muscle thelancet.com/journals/landi… #T2D

New EASO algorithm for the management of OBESITY ✍️Evidence presented refers to that available before January 31st, 2025 ✍️Some items could already be updated ✍️However, with all these weapons there’s no excuse not to fight this disease! #ECO2025 #semaglutide #tirzepatide

In the GRADE trial choice of second-line glucose-lowering medication class added to metformin is not associated with change in cognitive performance in persons with early #T2D jamanetwork.com/journals/jamai…

New journal for #Endocrinology! Here is my commentary: AACE Endocrinology and Diabetes: An Exciting New Endocrinology Journal sciencedirect.com/science/articl… #EndoTwitter

🧬 Breaking: Regeneron may have just improved upon basic GLP-1 weight loss therapy - - - New Phase 2 COURAGE trial top-line data suggest that combining semaglutide (Wegovy/Ozempic) with muscle-preserving antibodies could dramatically improve the quality of weight loss—not just

Checkout new publication in Endocrine Practice (AACE) by our pituitary center director Dr. Roberto Salvatori on pituitary stalk lesions! pubmed.ncbi.nlm.nih.gov/40472993/

AACE is pleased to announce a significant increase in the Journal Impact Factor for our flagship journal, Endocrine Practice, reaching 4.6 in the new Journal Citation Reports (JCR) from Clarivate published today. This is a 24% increase from last year's Impact Factor of 3.7. Read